FATE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.04 USD | -4.36% |
|
-15.29% | +34.76% |
| Mar. 21 | Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC | CI |
| Mar. 19 | Fate Therapeutics Prices $100 Million Offering, Private Placement | MT |
Presentation Operator MessageOperator (Operator)Welcome to the Fate Therapeutics Fourth Quarte...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Companyâs platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
5.04
USD
Average target price
7.8
USD
Spread / Average Target
+54.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.76% | 574M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.19% | 21.66B | |
| -18.35% | 20.77B | |
| -7.87% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Transcript : Fate Therapeutics, Inc., Q4 2022 Earnings Call, Feb 28, 2023
